[1] |
DROSSMAN D A, HASLER W L. RomeⅣ-functional GI disorders:disorders of gut-brain interaction[J]. Gastroenterology, 2016, 150(6):1257-1261. DOI: 10.1053/j.gastro.2016.03.035.
|
[2] |
MAKKER J, CHILIMURI S, BELLA J N. Genetic epidemiology of irritable bowel syndrome[J]. World J Gastroenterol, 2015, 21(40):11353-11361. DOI: 10.3748/wjg.v21.i40.11353.
|
[3] |
ZHOU Q Q, ZHANG B Y, VERNE G N. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome[J]. Pain, 2009, 146(1/2):41-46. DOI: 10.1016/j.pain.2009.06.017.
|
[4] |
DROSSMAN D A, TACK J, FORD A C,et al. Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction):a Rome foundation working team report[J]. Gastroenterology, 2018, 154(4):1140-1171.e1. DOI: 10.1053/j.gastro.2017.11.279.
|
[5] |
FORD A C, TALLEY N J. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome:a systematic review[J]. J Gastroenterol, 2011, 46(4):421-431. DOI: 10.1007/s00535-011-0379-9.
|
[6] |
O'MAHONY S M, CLARKE G, DINAN T G,et al. Irritable bowel syndrome and stress-related psychiatric co-morbidities:focus on early life stress[J]. Handb Exp Pharmacol, 2017, 239:219-246. DOI: 10.1007/164_2016_128.
|
[7] |
SINGH P, LEMBO A. Emerging role of the gut microbiome in irritable bowel syndrome[J]. Gastroenterol Clin North Am, 2021, 50(3):523-545. DOI: 10.1016/j.gtc.2021.03.003.
|
[8] |
DEFREES D N, BAILEY J. Irritable bowel syndrome:epidemiology,pathophysiology,diagnosis,and treatment[J]. Prim Care, 2017, 44(4):655-671. DOI: 10.1016/j.pop.2017.07.009.
|
[9] |
LOVELL R M, FORD A C. Global prevalence of and risk factors for irritable bowel syndrome:a meta-analysis[J]. Clin Gastroenterol Hepatol, 2012, 10(7):712-721.e4. DOI: 10.1016/j.cgh.2012.02.029.
|
[10] |
XIONG L S, CHEN M H, CHEN H X,et al. A population-based epidemiologic study of irritable bowel syndrome in South China:stratified randomized study by cluster sampling[J]. Aliment Pharmacol Ther, 2004, 19(11):1217-1224. DOI: 10.1111/j.1365-2036.2004.01939.x.
|
[11] |
LIU J S, HOU X H. A review of the irritable bowel syndrome investigation on epidemiology,pathogenesis and pathophysiology in China[J]. J Gastroenterol Hepatol, 2011, 26(Suppl 3):88-93. DOI: 10.1111/j.1440-1746.2011.06641.x.
|
[12] |
BLACK C J, FORD A C. Global burden of irritable bowel syndrome:trends,predictions and risk factors[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(8):473-486. DOI: 10.1038/s41575-020-0286-8.
|
[13] |
EVERHART J E, RUHL C E. Burden of digestive diseases in the United States partⅡ:lower gastrointestinal diseases[J]. Gastroenterology, 2009, 136(3):741-754. DOI: 10.1053/j.gastro.2009.01.015.
|
[14] |
SIMRÉN M, TÖRNBLOM H, PALSSON O S,et al. Management of the multiple symptoms of irritable bowel syndrome[J]. Lancet Gastroenterol Hepatol, 2017, 2(2):112-122. DOI: 10.1016/S2468-1253(16)30116-9.
|
[15] |
MOAYYEDI P, ANDREWS C N, MACQUEEN G,et al. Canadian association of gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS)[J]. J Can Assoc Gastroenterol, 2019, 2(1):6-29. DOI: 10.1093/jcag/gwy071.
|
[16] |
BIJKERK C J, DE WIT N J, MURIS J W M,et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial[J]. BMJ, 2009, 339:b3154. DOI: 10.1136/bmj.b3154.
|
[17] |
ZHENG L, LAI Y L, LU W M,et al. Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter,randomized,controlled trial[J]. Clin Gastroenterol Hepatol, 2015, 13(7):1285-1292.e1. DOI: 10.1016/j.cgh.2015.01.015.
|
[18] |
SAITO Y A, ALMAZAR A E, TILKES K E,et al. Randomised clinical trial:pregabalin vs placebo for irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2019, 49(4):389-397. DOI: 10.1111/apt.15077.
|
[19] |
EL-AYACHE N, GALLIGAN J J. 5-HT3 receptor signaling in serotonin transporter-knockout rats:a female sex-specific animal model of visceral hypersensitivity[J]. Am J Physiol Gastrointest Liver Physiol, 2019, 316(1):G132-143. DOI: 10.1152/ajpgi.00131.2018.
|
[20] |
JONES J, LEMBO A, HEIDELBAUGH J,et al. Management of irritable bowel syndrome with diarrhea:focus on eluxadoline[J]. Curr Med Res Opin, 2021, 37(4):567-578. DOI: 10.1080/03007995.2021.1888705.
|
[21] |
BRENNER D M, FOGEL R, DORN S D,et al. Efficacy,safety,and tolerability of plecanatide in patients with irritable bowel syndrome with constipation:results of two phase 3 randomized clinical trials[J]. Am J Gastroenterol, 2018, 113(5):735-745. DOI: 10.1038/s41395-018-0026-7.
|
[22] |
HÄUSER W, MARSCHALL U, LAYER P,et al. The prevalence,comorbidity,management and costs of irritable bowel syndrome[J]. Dtsch Arztebl Int, 2019, 116(27/28):463-470. DOI: 10.3238/arztebl.2019.0463.
|
[23] |
KOLOSKI N A, TALLEY N J, HUSKIC S S,et al. Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia[J]. Aliment Pharmacol Ther, 2003, 17(6):841-851. DOI: 10.1046/j.1365-2036.2003.01498.x.
|
[24] |
KONG S C, HURLSTONE D P, POCOCK C Y,et al. The incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases[J]. J Clin Gastroenterol,2005,39(2):138-141.
|
[25] |
|
[26] |
LARUSSA T, ROSSI M, SURACI E,et al. Use of complementary and alternative medicine by patients with irritable bowel syndrome according to the RomaⅣ criteria:a single-center Italian survey[J]. Medicina (Kaunas), 2019, 55(2):46. DOI: 10.3390/medicina55020046.
|
[27] |
LIU J P, YANG M, LIU Y X,et al. Herbal medicines for treatment of irritable bowel syndrome[J]. Cochrane Database Syst Rev, 2006(1):CD004116. DOI: 10.1002/14651858.CD004116.pub2.
|
[28] |
WERAWATGANON D, RAKANANURAK N, SALLAPANT S,et al. Aloe vera attenuated gastric injury on indomethacin-induced gastropathy in rats[J]. World J Gastroenterol, 2014, 20(48):18330-18337. DOI: 10.3748/wjg.v20.i48.18330.
|
[29] |
HONG S W, CHUN J, PARK S,et al. Aloe vera is effective and safe in short-term treatment of irritable bowel syndrome:a systematic review and meta-analysis[J]. J Neurogastroenterol Motil, 2018, 24(4):528-535. DOI: 10.5056/jnm18077.
|
[30] |
YANG H N, KIM D J, KIM Y M,et al. Aloe-induced toxic hepatitis[J]. J Korean Med Sci, 2010, 25(3):492-495. DOI: 10.3346/jkms.2010.25.3.492.
|
[31] |
|
[32] |
CHUMPITAZI B P, KEARNS G L, SHULMAN R J. Review article:the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders[J]. Aliment Pharmacol Ther, 2018, 47(6):738-752. DOI: 10.1111/apt.14519.
|
[33] |
ALAMMAR N, WANG L, SABERI B,et al. The impact of peppermint oil on the irritable bowel syndrome:a meta-analysis of the pooled clinical data[J]. BMC Complement Altern Med, 2019, 19(1):21. DOI: 10.1186/s12906-018-2409-0.
|
[34] |
FORD A C, MOAYYEDI P, CHEY W D,et al. American college of gastroenterology monograph on management of irritable bowel syndrome[J]. Am J Gastroenterol, 2018, 113(Suppl 2):1-18. DOI: 10.1038/s41395-018-0084-x.
|
[35] |
|
[36] |
BOURGEOIS P, GOOSSENS A. Allergic contact cheilitis caused by menthol in toothpaste and throat medication:a case report[J]. Contact Dermatitis, 2016, 75(2):113-115. DOI: 10.1111/cod.12571.
|
[37] |
ALLESCHER H D, ABDEL-AZIZ H. Mechanism of action of STW 5 in functional dyspepsia and IBS:the origin of multi-target[J]. Dig Dis, 2017, 35(Suppl 1):18-24. DOI: 10.1159/000485456.
|
[38] |
MADISCH A, HOLTMANN G, PLEIN K,et al. Treatment of irritable bowel syndrome with herbal preparations:results of a double-blind,randomized,placebo-controlled,multi-centre trial[J]. Aliment Pharmacol Ther, 2004, 19(3):271-279. DOI: 10.1111/j.1365-2036.2004.01859.x.
|
[39] |
张伟,孙建华,裴丽霞,等. 中医药治疗肠易激综合征的系统评价/Meta分析的再评价[J]. 世界华人消化杂志,2014,22(12):1747-1755.
|
[40] |
ACHAMRAH N, DÉCHELOTTE P, COËFFIER M. Glutamine and the regulation of intestinal permeability:from bench to bedside[J]. Curr Opin Clin Nutr Metab Care, 2017, 20(1):86-91. DOI: 10.1097/MCO.0000000000000339.
|
[41] |
|
[42] |
|
[43] |
SIAH K T, WONG R K, HO K Y. Melatonin for the treatment of irritable bowel syndrome[J]. World J Gastroenterol, 2014, 20(10):2492-2498. DOI: 10.3748/wjg.v20.i10.2492.
|
[44] |
BARBALHO S M, GOULART R A, ARAÚJO A C,et al. Irritable bowel syndrome:a review of the general aspects and the potential role of vitamin D[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(4):345-359. DOI: 10.1080/17474124.2019.1570137.
|
[45] |
ABBASNEZHAD A, AMANI R, HASANVAND A,et al. Association of serum vitamin D concentration with clinical symptoms and quality of life in patients with irritable bowel syndrome[J]. J Am Coll Nutr, 2019, 38(4):327-333. DOI: 10.1080/07315724.2018.1510349.
|
[46] |
GLABSKA D, KOLOTA A, LACHOWICZ K,et al. Vitamin D supplementation and mental health in inflammatory bowel diseases and irritable bowel syndrome patients:a systematic review[J]. Nutrients, 2021, 13(10):3662. DOI: 10.3390/nu13103662.
|
[47] |
JALILI M, VAHEDI H, POUSTCHI H,et al. Effects of vitamin D supplementation in patients with irritable bowel syndrome:a randomized,double-blind,placebo-controlled clinical trial[J]. Int J Prev Med, 2019, 10:16. DOI: 10.4103/ijpvm.IJPVM_512_17.
|
[48] |
KHALIGHI SIKAROUDI M, MOKHTARE M, JANANI L,et al. Vitamin D3 supplementation in diarrhea-predominant irritable bowel syndrome patients:the effects on symptoms improvement,serum corticotropin-releasing hormone,and interleukin-6 - a randomized clinical trial[J]. Complement Med Res, 2020, 27(5):302-309. DOI: 10.1159/000506149.
|
[49] |
PLUDOWSKI P, HOLICK M F, GRANT W B,et al. Vitamin D supplementation guidelines[J]. J Steroid Biochem Mol Biol, 2018, 175:125-135. DOI: 10.1016/j.jsbmb.2017.01.021.
|
[50] |
DROSSMAN D A, HASLER W L. RomeⅣ-functional GI disorders:disorders of gut-brain interaction[J]. Gastroenterology, 2016, 150(6):1257-1261. DOI: 10.1053/j.gastro.2016.03.035.
|
[51] |
GWEE K A, GONLACHANVIT S, GHOSHAL U C,et al. Second Asian consensus on irritable bowel syndrome[J]. J Neurogastroenterol Motil, 2019, 25(3):343-362. DOI: 10.5056/jnm19041.
|
[52] |
KOLOSKI N A, JONES M, KALANTAR J,et al. The brain—gut pathway in functional gastrointestinal disorders is bidirectional:a 12-year prospective population-based study[J]. Gut, 2012, 61(9):1284-1290. DOI: 10.1136/gutjnl-2011-300474.
|
[53] |
|
[54] |
|
[55] |
KOLOSKI N, HOLTMANN G, TALLEY N J. Is there a causal link between psychological disorders and functional gastrointestinal disorders? [J]. Expert Rev Gastroenterol Hepatol, 2020, 14(11):1047-1059. DOI: 10.1080/17474124.2020.1801414.
|
[56] |
LACKNER J M. Skills over pills? A clinical gastroenterologist's primer in cognitive behavioral therapy for irritable bowel syndrome[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(7):601-618. DOI: 10.1080/17474124.2020.1780118.
|
[57] |
ZIJDENBOS I L, DE WIT N J, VAN DER HEIJDEN G J,et al. Psychological treatments for the management of irritable bowel syndrome[J]. Cochrane Database Syst Rev, 2009(1):CD006442. DOI: 10.1002/14651858.CD006442.pub2.
|
[58] |
EVERITT H A, LANDAU S, O'REILLY G,et al. Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB):a multicentre randomised trial[J]. Gut, 2019, 68(9):1613-1623. DOI: 10.1136/gutjnl-2018-317805.
|
[59] |
EVERITT H, LANDAU S, LITTLE P,et al. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome:the ACTIB three-arm RCT[J]. Health Technol Assess, 2019, 23(17):1-154. DOI: 10.3310/hta23170.
|
[60] |
EVERITT H A, LANDAU S, O'REILLY G,et al. Cognitive behavioural therapy for irritable bowel syndrome:24-month follow-up of participants in the ACTIB randomised trial[J]. Lancet Gastroenterol Hepatol, 2019, 4(11):863-872. DOI: 10.1016/S2468-1253(19)30243-2.
|
[61] |
WEBB A N, KUKURUZOVIC R H, CATTO-SMITH A G,et al. Hypnotherapy for treatment of irritable bowel syndrome[J]. Cochrane Database Syst Rev, 2007(4):CD005110. DOI: 10.1002/14651858.CD005110.pub2.
|
[62] |
MOSER G, TRÄGNER S, GAJOWNICZEK E E,et al. Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome:a randomized controlled trial[J]. Am J Gastroenterol, 2013, 108(4):602-609. DOI: 10.1038/ajg.2013.19.
|
[63] |
FLIK C E, LAAN W, ZUITHOFF N P A,et al. Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE):a multicentre randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2019, 4(1):20-31. DOI: 10.1016/S2468-1253(18)30310-8.
|
[64] |
D'SILVA A, MACQUEEN G, NASSER Y,et al. Yoga as a therapy for irritable bowel syndrome[J]. Dig Dis Sci, 2020, 65(9):2503-2514. DOI: 10.1007/s10620-019-05989-6.
|
[65] |
SCHUMANN D, ANHEYER D, LAUCHE R,et al. Effect of Yoga in the therapy of irritable bowel syndrome:a systematic review[J]. Clin Gastroenterol Hepatol, 2016, 14(12):1720-1731. DOI: 10.1016/j.cgh.2016.04.026.
|
[66] |
TAVAKOLI T, DAVOODI N, JAFAR TABATABAEE T S,et al. Comparison of laughter Yoga and anti-anxiety medication on anxiety and gastrointestinal symptoms of patients with irritable bowel syndrome[J]. Middle East J Dig Dis, 2019, 11(4):211-217. DOI: 10.15171/mejdd.2019.151.
|
[67] |
HENRICH J F, GJELSVIK B, SURAWY C,et al. A randomized clinical trial of mindfulness-based cognitive therapy for women with irritable bowel syndrome-effects and mechanisms[J]. J Consult Clin Psychol, 2020, 88(4):295-310. DOI: 10.1037/ccp0000483.
|
[68] |
GAYLORD S A, PALSSON O S, GARLAND E L,et al. Mindfulness training reduces the severity of irritable bowel syndrome in women:results of a randomized controlled trial[J]. Am J Gastroenterol, 2011, 106(9):1678-1688. DOI: 10.1038/ajg.2011.184.
|
[69] |
NALIBOFF B D, SMITH S R, SERPA J G,et al. Mindfulness-based stress reduction improves irritable bowel syndrome (IBS) symptoms via specific aspects of mindfulness[J]. Neurogastroenterol Motil, 2020, 32(9):e13828. DOI: 10.1111/nmo.13828.
|
[70] |
|
[71] |
|
[72] |
ZHU J J, LIU S, SU X L,et al. Efficacy of Chinese herbal medicine for diarrhea-predominant irritable bowel syndrome:a meta-analysis of randomized,double-blind,placebo-controlled trials[J]. Evid Based Complement Alternat Med, 2016, 2016:4071260. DOI: 10.1155/2016/4071260.
|
[73] |
WU Y B, DAI Y K, ZHANG L,et al. Pharmacological treatments of Chinese herbal medicine for irritable bowel syndrome in adults:a network meta-analysis of randomized controlled trials[J]. PLoS One, 2021, 16(8):e0255665. DOI: 10.1371/journal.pone.0255665.
|
[74] |
XIAO Y, LIU Y Y, HUANG S H,et al. The efficacy of Shugan Jianpi Zhixie therapy for diarrhea-predominant irritable bowel syndrome:a meta-analysis of randomized,double-blind,placebo-controlled trials[J]. PLoS One, 2015, 10(4):e0122397. DOI: 10.1371/journal.pone.0122397.
|
[75] |
CHEN M, TANG T C, WANG Y,et al. Randomised clinical trial:Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2018, 48(2):160-168. DOI: 10.1111/apt.14817.
|
[76] |
RAHIMI R, ABDOLLAHI M. Herbal medicines for the management of irritable bowel syndrome:a comprehensive review[J]. World J Gastroenterol, 2012, 18(7):589-600. DOI: 10.3748/wjg.v18.i7.589.
|
[77] |
世界卫生组织推荐针灸治疗的43种病症[J]. 中医药临床杂志,2012,24(6):519.
|
[78] |
MANHEIMER E, CHENG K, WIELAND L S,et al. Acupuncture for treatment of irritable bowel syndrome[J]. Cochrane Database Syst Rev, 2012, 5(5):CD005111. DOI: 10.1002/14651858.CD005111.pub3.
|
[79] |
ZHENG H, LI Y, ZHANG W,et al. Electroacupuncture for patients with diarrhea-predominant irritable bowel syndrome or functional diarrhea:a randomized controlled trial[J]. Medicine, 2016, 95(24):e3884. DOI: 10.1097/MD.0000000000003884.
|
[80] |
PEI L X, GENG H, GUO J,et al. Effect of acupuncture in patients with irritable bowel syndrome:a randomized controlled trial[J]. Mayo Clin Proc, 2020, 95(8):1671-1683. DOI: 10.1016/j.mayocp.2020.01.042.
|
[81] |
|
[82] |
|
[83] |
|
[84] |
BU F L, HAN M, LU C L,et al. A systematic review of Tuina for irritable bowel syndrome:recommendations for future trials[J]. Complement Ther Med, 2020, 52:102504. DOI: 10.1016/j.ctim.2020.102504.
|
[85] |
SPILLER R, AZIZ Q, CREED F,et al. Guidelines on the irritable bowel syndrome:mechanisms and practical management[J]. Gut, 2007, 56(12):1770-1798. DOI: 10.1136/gut.2007.119446.
|